stockrow
Friday 6 November 2026
Export XLO’s income statement to Excel — free account
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, up 589.9% from fiscal 2024.
- Revenue
- +131.2%
- EPS
- +85.3%
- Free cash flow
- −26.2%
Quarter to June 2026, against a year earlier
8.63
0.13
+1.53%
Follow XLO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 6 | 44 | 64 | +589.9% | 40 | 50 | 7 | (45.2%) | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (17) | (55) | (76) | (88) | (76) | (58) | (35) | (22) | +12.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (918.05) | (80.05) | (34.06) | (80.0) pt | ||||||
| Net income | — | 0 | — | (17) | (55) | (76) | (88) | (76) | (58) | (35) | (22) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.66 | 5.24 | 3.30 | n/m | |||||
| Earnings | — | — | — | (0.63) | (1,476.51) | (189.36) | (45.10) | (38.94) | (15.27) | (4.19) | (1.49) | +37.1% | ||||||
| Cash flow | — | — | — | (0.66) | (965.00) | (201.73) | (38.72) | (34.95) | (4.81) | (0.60) | (3.12) | (1.6%) | ||||||
| Capex | — | — | — | 0.00 | (58.50) | (2.75) | (0.95) | (0.25) | (0.01) | (0.06) | (0.03) | n/m | ||||||
| Free cash flow | — | — | — | (0.66) | (1,023.50) | (204.47) | (39.67) | (35.20) | (4.82) | (0.66) | (3.16) | +0.1% | ||||||
| Book value | — | — | — | 1.40 | (141.31) | 463.23 | 54.02 | 18.76 | 4.60 | 4.22 | 3.72 | +20.2% | ||||||
| Shares, m | — | — | — | 27 | 0 | 0 | 2 | 2 | 4 | 8 | 14 | (18.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 1.71 | 2.61 | 0.9 | ||||||
| P/B | — | — | — | — | — | — | — | — | 2.90 | 2.12 | 2.32 | 2.5 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (1.40) | 0.51 | (0.7) | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.14 | 11.09 | (0.54) | 5.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (18) | (36) | (81) | (76) | (69) | (18) | (5) | (61) | (19.3%) | |||||
| Capex | — | — | — | (1) | (2) | (1) | (2) | 0 | 0 | (1) | (1) | (5.2%) | ||||||
| Free cash flow | — | — | — | (18) | (38) | (82) | (78) | (69) | (18) | (6) | (61) | (17.9%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 46 | (2) | 190 | 103 | 32 | 33 | 89 | 111 | +11.6% | |||||
| Net debt | — | — | — | (30) | (12) | (188) | (117) | (45) | (55) | (138) | (136) | +28.7% | ||||||
| Shareholders’ equity | — | — | — | 39 | (5) | 185 | 106 | 37 | 18 | 35 | 72 | (1.5%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (55.20) | (111.51) | (59.60) | (49.39) | (76.37) | (88.24) | (31.04) | (15.16) | +24.2 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 30.69 | 97.90 | (148.42) | (60.62) | (107.25) | (214.02) | (132.53) | (55.03) | (163.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 74 | 89 | 73 | 64 | 76 | — | +0.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.10 | 0.58 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Xilio Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| GOSS Gossamer Bio, Inc. | $57.6M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| XBIT XBiotech Inc. | $57.0M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLNN Clene Inc. | $56.4M | — (loss-making) | — (loss-making) | +273.33% (above 0%: growing) | n/m | −16.61% (below 0%: shrinking) | 71.43% | (11,333.93%) | Compare |
| XLO Xilio Therapeutics, Inc. | $55.9M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLD Boundless Bio, Inc. | $54.8M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | Compare |
| Median of peers | $56.7M | — | — | −16.82% | — | −28.98% | 76.90% | (141.12%) |